Osteoporosis is characterized by reduction in the density and quality of bones that often result in broken bones in the wrist, hip, and spine. Various factors responsible for osteoporosis include, genetic factors, low intake of calcium, magnesium, and vitamin D, eating disorders such as anorexia, inactivity and immobility, and excessive alcohol intake. Moreover, conditions that increase the risk of osteoporosis include, cancer, chronic kidney diseases, chronic obstructive pulmonary disease, and some autoimmune diseases such as rheumatoid arthritis.
Global osteoporosis treatment market is estimated to be valued at US$ 14.01 billion in 2022 and is expected to exhibit a CAGR of 3.8% during the forecast period (2022-2030).
Figure 1.Global Osteoporosis Treatment Market Share (%), by Distribution Channel, 2022
Increasing launches and approvals of novel osteoporosis treatment drugs are expected to drive growth of the osteoporosis market
Increasing approvals and launches of novel osteoporosis drugs is expected to significantly drive the osteoporosis treatment market growth over the forecast period. For instance, in January 2019, Amgen Inc., a biopharmaceutical company, and UCB, Brussels, Belgium, a global biopharmaceutical company, announced that the Japanese Ministry of Health, Labor and Welfare had granted a marketing authorization for EVENITY (romosozumab) for the treatment of osteoporosis in patients at high risk of fracture.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 14.01 Bn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 3.8% | 2030 Value Projection: | US$ 18.92 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED, Amgen Inc., Dr. Reddy’s Laboratories Ltd., Viatris Inc., Ligand Pharmaceuticals Incorporated, Eli Lilly and Company, Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co., Inc., GSK plc., and Pfizer Inc |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2.Global Osteoporosis Treatment Market Share (%), by Region, 2022\
Increasing incidence of osteoporosis is expected to drive market growth during the forecast period.
Increasing prevalence and incidence of osteoporosis is expected to drive market growth during the forecast period. For instance, according to the INTERNATIONAL OSTEOPOROSIS FOUNDATION, osteoporosis causes more than 8.9 billion fractures annually worldwide, resulting in an osteoporosis fracture every 3 seconds.
Global Osteoporosis Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, UAE, Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another.
The COVID-19 pandemic had a negative impact on the osteoporosis treatment market, owing to disruption of fracture liaison services. Moreover, during the pandemic, hospitals and private health clinics cancelled non-emergency procedures and office visits, and several U.S. citizens postponed care to stop the spread of the virus, which further affected the osteoporosis market. A Morbidity and Mortality Weekly Report by the Centers for Disease Control and Prevention (CDC) acknowledged that by the end of June 2020, an estimated 41% of adults in the U.S. had delayed or avoided medical care including urgent or emergency care (12%) and routine care (32%) because of concerns or changes in healthcare delivery related to COVID-19.
Global Osteoporosis Treatment Market: Key Developments
In January 2021, Theramex, a global pharmaceutical company, launched Livogiva, a new teriparatide pre-filled pen for the treatment of severe osteoporosis in Europe.
In August 2021, Enzene Biosciences, a technology driven company based in Pune, India, announced marketing authorization from the Drug Controller General of India (DCGI) for its third biosimilar drug 'Denosumab', indicated for the treatment of osteoporosis in adults
Global Osteoporosis Treatment Market: Restraint
The major factors that hinder growth of the global osteoporosis treatment market include product recalls and side effects associated with osteoporosis drugs such as pain in the joints, muscles, or bones, nausea, dizziness, etc. For instance, in April 2022, Macleods Pharmaceuticals Ltd., a pharmaceutical company, recalled 4,872 bottles of a drug used to treat or prevent osteoporosis, manufactured at Baddi (Himachal Pradesh), India due to failed content uniformity specifications.
Key Players
Major players operating in the global osteoporosis treatment market include Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED, Amgen Inc., Dr. Reddy’s Laboratories Ltd., Viatris Inc., Ligand Pharmaceuticals Incorporated, Eli Lilly and Company, Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co., Inc., GSK plc., and Pfizer Inc.
Osteoporosis is a bone related disease that weakens bones and increases the risk of fracture and breaking of bones. The factors responsible for osteoporosis include, long-term use of high-dose oral corticosteroids, a family history of osteoporosis – particularly history of a hip fracture in a parent, having a low body mass index (BMI), heavy drinking and smoking, and others. Osteoporosis treatment involves preventing and treating fractures and using medication to strengthen bones. The treatment usually includes medications such as Bisphosphonates that are the most common drugs prescribed for osteoporosis. Furthermore, hormone therapy treatment is recommended for post-menopausal women, as they experience a drop in the levels of estrogen, which weakens the bones.
Market Dynamics
Increasing approvals and launches of novel osteoporosis drugs is expected to significantly drive the osteoporosis treatment market growth over the forecast period. For instance, in October 2019, the U.S. Food and Drug Administration had announced the approval of the new drug application (NDA) for PF708 submitted under the 505(b)(2) regulatory pathway, with teriparatide injection as the reference drug to Pfenex, a biotechnology company. Like teriparatide injection, the FDA-approved PF708 product is indicated for the treatment of osteoporosis in certain patients at high risk for fracture.
Moreover, in August 2020, Cadila Pharmaceuticals, a multinational pharmaceutical company, had announced the launch of NuPTH an osteoporosis biosimilar of Forteo in India. The Forteo biosimilar is used for treatment of osteoporosis and in patients with increased risk of fracture. The biosimilar NuPTH aims to be a cost effective solution for patients with osteoporosis and will be sold as an easy to use, pre-filled disposable pen.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients